Clarus Ventures Promotes Michele Park, Ph.D., To Partner

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 18, 2015 /PRNewswire/ -- Clarus Ventures, a leading life science investment firm, announced today the promotion of Michele Park, Ph.D., to Partner.  Michele is based in the firm's South San Francisco office.

Dr. Park, who joined Clarus in 2006, represents the firm as a board member of SFJ Pharmaceuticals IV L.P. She has served as a director of Sientra Inc. and board observer at Achillion Pharmaceuticals, Inc.  Prior to joining Clarus, she was an equity research analyst covering the biotechnology sector for Credit Suisse First Boston.

"We are pleased to announce Michele's promotion to partner," said Kurt Wheeler, managing director.  "She has a deep scientific background and has actively participated in all phases of the Clarus investment process. This has included her work in identifying promising investment opportunities for the firm."

Dr. Park commented, "It has been a unique privilege to work with each of the Clarus team members. I look forward to continuing to contribute to the successful development of our current and future portfolio."

Dr. Park received her Ph.D. in molecular biology from Cornell University's Graduate School of Biomedical Sciences and completed her dissertation at Memorial Sloan-Kettering Cancer Center. She also holds a B.A. in Molecular Biology from Princeton University.

Clarus Ventures is led by Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon and Kurt Wheeler. The Clarus team includes Partners Emmett Cunningham and Michele Park, Principal Finny Kuruvilla, Associate Ari Brettman, Senior Advisors Jeff Leiden and Edward Scolnick, and Venture Partners Barry Gertz and William Young.

About Clarus Ventures

Clarus Ventures is a leading global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, Clarus manages over $1.7 billion invested in more than 50 private and public companies in the biotechnology, medical device and diagnostic spaces. In every investment, Clarus employs a hands-on philosophy and adheres to investment principles that are founded on core competencies in drug development, complex partnership structuring and the ability to adapt to an ever-changing investment landscape. Clarus strives to generate outstanding returns for its investors by identifying and financing innovative medicines that improve people's lives. Clarus has offices in Cambridge, MA, and South San Francisco, CA. For more information please visit,


Media Contacts

Sarah Parker

Tony Russo

Clarus Ventures, 617 949 2176

Russo Partners, 212 845 4251


Editor's Note: Photograph available on request

To view the original version on PR Newswire, visit:

SOURCE Clarus Ventures, LLC